Literature DB >> 20124128

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

Glenn N Levine, Anthony V D'Amico, Peter Berger, Peter E Clark, Robert H Eckel, Nancy L Keating, Richard V Milani, Arthur I Sagalowsky, Matthew R Smith, Neil Zakai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20124128      PMCID： PMC3023973          DOI： 10.1161/CIRCULATIONAHA.109.192695

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  43 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Transperineal brachytherapy in patients with large prostate glands.

Authors:  H Wang; K Wallner; S Sutlief; J Blasko; K Russell; W Ellis
Journal:  Int J Cancer       Date:  2000-08-20       Impact factor: 7.396

3.  Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

Authors:  James W Denham; Allison Steigler; David S Lamb; David Joseph; Hedy Mameghan; Sandra Turner; John Matthews; Ian Franklin; Chris Atkinson; John North; Michael Poulsen; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Gillian Duchesne; Olga Kovacev; Catherine D'Este
Journal:  Lancet Oncol       Date:  2005-11       Impact factor: 41.316

4.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Authors:  Alfredo Berruti; Luigi Dogliotti; Carlo Terrone; Stefania Cerutti; Giancarlo Isaia; Roberto Tarabuzzi; Giuseppe Reimondo; Mauro Mari; Paola Ardissone; Stefano De Luca; Giuseppe Fasolis; Dario Fontana; Salvatore Rocca Rossetti; Alberto Angeli
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

5.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

6.  Changes in body composition during androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Joel S Finkelstein; Francis J McGovern; Anthony L Zietman; Mary Anne Fallon; David A Schoenfeld; Philip W Kantoff
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

7.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

Authors:  Frances Dockery; Christopher J Bulpitt; Sanjiv Agarwal; Mandy Donaldson; Chakravarthi Rajkumar
Journal:  Clin Sci (Lond)       Date:  2003-02       Impact factor: 6.124

10.  Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

Authors:  Shabbir M H Alibhai; Minh Duong-Hua; Rinku Sutradhar; Neil E Fleshner; Padraig Warde; Angela M Cheung; Lawrence F Paszat
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544
View more
  96 in total

1.  Cardiac and cognitive effects of androgen deprivation therapy: are they real?

Authors:  S M H Alibhai; H Z Mohamedali
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

2.  Prostate cancer: Cardiac mortality associated with ADT plus radiotherapy.

Authors:  Michel Bolla; Gilles Créhange
Journal:  Nat Rev Urol       Date:  2015-12-15       Impact factor: 14.432

3.  Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis.

Authors:  Huei-Ting Tsai; David F Penson; Kepher H Makambi; John H Lynch; Stephen K Van Den Eeden; Arnold L Potosky
Journal:  Urology       Date:  2013-08       Impact factor: 2.649

4.  Cancer Survivorship and Subclinical Myocardial Damage.

Authors:  Roberta Florido; Alexandra K Lee; John W McEvoy; Ron C Hoogeveen; Silvia Koton; Mara Z Vitolins; Chetan Shenoy; Stuart D Russell; Roger S Blumenthal; Chiadi E Ndumele; Christie M Ballantyne; Corinne E Joshu; Elizabeth A Platz; Elizabeth Selvin
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

Review 5.  Cardiovascular prevention in the cancer survivor.

Authors:  Carol L Chen
Journal:  Curr Atheroscler Rep       Date:  2015-03       Impact factor: 5.113

Review 6.  Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Thomas W Storer; Renee Miciek; Thomas G Travison
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

7.  Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

Authors:  Arnold L Potosky; Reina Haque; Andrea E Cassidy-Bushrow; Marianne Ulcickas Yood; Miao Jiang; Huei-Ting Tsai; George Luta; Nancy L Keating; Matthew R Smith; Stephen K Van Den Eeden
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

8.  Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes.

Authors:  Joe-Elie Salem; Tao Yang; Javid J Moslehi; Xavier Waintraub; Estelle Gandjbakhch; Anne Bachelot; Francoise Hidden-Lucet; Jean-Sebastien Hulot; Bjorn C Knollmann; Benedicte Lebrun-Vignes; Christian Funck-Brentano; Andrew M Glazer; Dan M Roden
Journal:  Circulation       Date:  2019-08-05       Impact factor: 29.690

9.  Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.

Authors:  Nancy L Keating; Pang-Hsiang Liu; A James O'Malley; Stephen J Freedland; Matthew R Smith
Journal:  Eur Urol       Date:  2013-02-22       Impact factor: 20.096

Review 10.  The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis.

Authors:  Ashley Bigaran; Eva Zopf; Jason Gardner; Andre La Gerche; Declan G Murphy; Erin J Howden; Michael K Baker; Prue Cormie
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-08-28       Impact factor: 5.554
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.